All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What novel therapies are under investigation for the treatment of high-risk MPN?
By Sabina Ray
Featured
Bookmark this article
During the ESH 10th Translational Research Conference: Myeloproliferative Neoplasms, the MPN Hub spoke to Prithviraj Bose, MD Anderson Cancer Center, Houston, US. We asked, What novel therapies are under investigation for the treatment of high-risk MPN?
What novel therapies are under investigation for the treatment of high-risk MPN?
Bose provides an overview of novel therapies for high-risk MPN, beginning with a discussion on spleen response and adverse events from the phase III MANIFEST-2 (NCT04603495) and TRANSFORM-1 (NCT04472598) trials investigating pelabresib and navitoclax in combination with ruxolitinib. Then, he reviews combination therapies, summarizing the current status of selinexor and vorinostat in combination with ruxolitinib as first-line and add-on treatments. Finally, Bose discusses the role of cellular and immunotherapies, such as JNJ-88549968 and AJ1-10502, to minimize the risk of cytopenias; he also highlights emerging treatments of interest.
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox